Efficacy Study of Diazoxide Choline to Treat Hypertriglyceridemia

This study has been completed.
Sponsor:
Collaborator:
Medpace, Inc.
Information provided by (Responsible Party):
Essentialis, Inc.
ClinicalTrials.gov Identifier:
NCT01211847
First received: September 29, 2010
Last updated: January 9, 2014
Last verified: January 2014

September 29, 2010
January 9, 2014
October 2010
September 2011   (final data collection date for primary outcome measure)
Triglyceride-lowering efficacy of DCCR [ Time Frame: 84 days ] [ Designated as safety issue: No ]
Fasting triglycerides (percent change from Baseline to Day 84)
Same as current
Complete list of historical versions of study NCT01211847 on ClinicalTrials.gov Archive Site
Improvement in other lipid profiles with DCCR [ Time Frame: 84 days ] [ Designated as safety issue: No ]
Apolipoprotein B (Apo B) (percent change from Baseline to Day 84) Fasting non-HDL cholesterol (percent change from Baseline to Day 84)
Same as current
Not Provided
Not Provided
 
Efficacy Study of Diazoxide Choline to Treat Hypertriglyceridemia
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy, Safety and Tolerability of Diazoxide Choline Controlled-Release Tablet (DCCR) in Subjects Without Diabetes Mellitus Having Very High Fasting Triglyceride Levels, With Double-Blind DCCR-Fenofibrate Combination Extension

Once a day oral administration with DCCR helps lower triglycerides

The population will consist of Statin-naive and Statin-treated subjects, all without diabetes mellitus, with fasting triglyceride levels in the range of ≥ 500 mg/dL and < 1500 mg/dL.

Subjects will be randomly assigned to 1 of 2 treatment groups: DCCR and Placebo

Approximately 44 subjects will be enrolled in the study and stratified by Statin use at a 1:1 ratio in each treatment group,

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Hypertriglyceridemia
  • Dyslipidemia
  • Drug: Diazoxide Choline Controlled-Release Tablet
    DCCR 290 mg once a day for 126 days
  • Drug: Placebo
    Placebo matching DCCR
  • Experimental: DCCR
    DCCR Treatment with 290 mg Diazoxide Choline
    Intervention: Drug: Diazoxide Choline Controlled-Release Tablet
  • Placebo Comparator: Placebo
    Placebo matching DCCR
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
44
December 2011
September 2011   (final data collection date for primary outcome measure)

INCLUSION CRITERIA:

Fasting triglycerides

  • Difference between Visit 3 (7 days prior to Baseline Visit) and Visit 4 (3 days prior to Baseline Visit) ≤ 60% (compared to the higher value of Visit 3 or Visit 4)
  • Run-in Triglycerides* ≥ 500 mg/dL and < 1500 mg/dL *Run-in Triglyceride is defined as the average fasting triglycerides for Visit 3 (7 days prior to Baseline Visit) and Visit 4 (3 days prior to Baseline Visit).

Statin use • Either Statin-naive

  • Must not be on statin at Screening and remaining as such during the Run-in/Washout Period and throughout the study

    • Or Statin-treated

  • Must be on Lipitor 20 mg initiated at the start of the Run-in/Washout Period and continue throughout the study

Medication washout

  • All subjects must be willing to undergo washout of all other lipid-lowering medications

Glycemic status

  • Fasting glucose < 126 mg/dL at Screening Visit
  • HbA1c < 6.5% at Screening Visit

EXCLUSION CRITERIA:

Medications: recent, current, anticipated

  • Administration of investigational drugs within 1 month prior to Screening Visit
  • Thyroid hormones or preparations within 1 month prior to Screening Visit (except in subjects on stable dose of replacement therapy for at least 1 month)
  • Thiazide diuretics within 2 weeks prior to Screening Visit
  • Discontinuation of beta-blockers within 1 month prior to Screening Visit or planned discontinuation of beta-blocker therapy
  • Anticipated requirement for use of prohibited concomitant medications

History of allergic reaction or significant intolerance to:

  • Diazoxide
  • Thiazides
  • Sulfonamides
  • Fenofibrate or fenofibric acid derivatives

Lifestyle changes

• Subjects intending to change exercise habits, quit smoking and/or quit alcohol use during the entire study

Specific diagnoses, medical conditions and history

  • Known type I or III hyperlipidemia
  • Known type 1 DM
  • Current diagnosis of type 2 DM
  • Any other clinically significant endocrine, cardiovascular, pulmonary, neurological, psychiatric, hepatic, gastrointestinal, hematological, renal, or dermatological disease interfering with the assessments of the study medications, according to the Investigator

Specific laboratory test results

• Any relevant biochemical abnormality interfering with the assessments of the study medications

Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01211847
CT013
No
Essentialis, Inc.
Essentialis, Inc.
Medpace, Inc.
Study Director: Alain Baron, M.D. Essentialis, Inc.
Essentialis, Inc.
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP